Journal
SCIENTIFIC REPORTS
Volume 9, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-018-37328-6
Keywords
-
Categories
Funding
- Institute of Health Carlos III, ISCIII, Spanish Health Ministry as part of the State Plan for Scientific and Technical Research and Innovation [RD06/0006/0035, RD12/0017/0037]
- ISCIII- Sub-Directorate General for Research Assessment and Promotion
- European Regional Development Fund (ERDF)
- Foundation for Research and Prevention of AIDS in Spain (FIPSE)
- ISCIII through the Spanish AIDS Research Network as part of the State Plan for Scientific and Technical Research and Innovation [RIS C03/173, RD12/0017/0018]
- Instituto de Salud Carlos III (ISCII) [PI14/01094, PI17/00657, PI14/01581, PI17/00903, PI14CIII/00011, PI17CIII/00003]
- Ministerio de Sanidad, Servicios Sociales e Igualdad [EC11-241]
- Plan Nacional R + D + I [RD16CIII/0002/0002, RD16/0025/0017, RD16/0025/0018]
- ISCIII- Subdireccion General de Evaluacion
- Fondo Europeo de Desarrollo Regional (FEDER)
- Programa de Intensificacion de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS) [INT15/00079, INT16/00100]
Ask authors/readers for more resources
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm(3) had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells >= 350 cells/mm(3) (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm(3).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available